Merrimack Pharmaceuticals Inc (MACK)
14.72
+0.04
(+0.31%)
USD |
NASDAQ |
Apr 19, 16:00
14.72
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 213.98M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 16.42% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 210552.8 |
| Price to Book Value | 11.41 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.30% |
Profile
| Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products. |
| URL | https://www.merrimack.com |
| Investor Relations URL | http://investors.merrimackpharma.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Mar. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 13, 2019 |
Ratings
Profile
| Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products. |
| URL | https://www.merrimack.com |
| Investor Relations URL | http://investors.merrimackpharma.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Mar. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 13, 2019 |